Peel Hunt reaffirmed their add rating on shares of Abcam (LON:ABC) in a research note issued to investors on Thursday, ThisIsMoney.Co.Uk reports.
A number of other research firms also recently commented on ABC. Royal Bank of Canada reaffirmed a sector performer rating and set a GBX 1,300 ($16.99) price objective on shares of Abcam in a research report on Tuesday, November 12th. JPMorgan Chase & Co. decreased their target price on shares of Abcam from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) and set a neutral rating on the stock in a report on Monday, September 16th. Liberum Capital restated a hold rating and issued a GBX 1,230 ($16.07) target price on shares of Abcam in a research report on Monday, November 11th. Finally, Berenberg Bank reaffirmed a buy rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a report on Monday, September 9th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Abcam presently has an average rating of Hold and an average target price of GBX 1,272.33 ($16.63).
Shares of ABC traded up GBX 27 ($0.35) during trading hours on Thursday, hitting GBX 1,371 ($17.91). 156,221 shares of the company were exchanged, compared to its average volume of 497,233. The company has a market cap of $2.83 billion and a price-to-earnings ratio of 62.89. Abcam has a fifty-two week low of GBX 1,006 ($13.15) and a fifty-two week high of GBX 1,523 ($19.90). The firm’s fifty day moving average is GBX 1,238.50 and its 200 day moving average is GBX 1,281.12.
In related news, insider Alan Thomas Hirzel sold 25,381 shares of Abcam stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of GBX 1,171 ($15.30), for a total transaction of £297,211.51 ($388,359.48). Also, insider Jonathan Simon Milner sold 170,000 shares of Abcam stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of GBX 1,147 ($14.99), for a total transaction of £1,949,900 ($2,547,889.72). Insiders have sold a total of 199,884 shares of company stock valued at $229,858,080 in the last three months.
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
See Also: What is a CD ladder?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.